靶向DNA和组蛋白表观遗传修饰治疗肾脏病
本综述聚焦DNA与组蛋白表观遗传修饰在肾脏病发病中的作用及治疗潜力。临床前证据显示,多种表观遗传调节药物对急性肾损伤、慢性肾脏病及AKI向CKD转化具有有益作用,但部分药物存在肾毒性,需谨慎。
要点
- DNA和组蛋白表观遗传修饰参与AKI、CKD及AKI向CKD转化的发病。
- 多种表观遗传调节药物在临床前肾脏损伤中显示有益作用。
- 部分表观遗传药物有肾毒性报道,临床转化需谨慎。
核心结论
- 表观遗传调节剂可能为肾脏病提供新疗法,但需基于部分药物的临床肾毒性保持谨慎。
研究设计与样本
- 综述,聚焦DNA和组蛋白表观遗传修饰在肾脏病发病中的作用及治疗意义。
主要发现
- 多种病因的AKI、CKD及AKI向CKD转化中存在表观遗传调控机制激活的证据。
- 减少DNA甲基化、减少组蛋白甲基化、增加组蛋白乙酰化、增加组蛋白巴豆酰化或干扰组蛋白修饰阅读器的药物在临床前肾脏损伤中显示有益作用。
- 大多数临床前研究针对CKD或AKI向CKD转化。
- 巴豆酸盐给药对肾毒性AKI具有保护作用,但DNA甲基化抑制剂对临床前AKI的证据存在矛盾。
- BET抑制剂阿帕他隆(apabetalone)正在3期试验中用于动脉粥样硬化,肾功能为次要终点,但DNA和HDAC抑制剂有肾毒性报道。
临床怎么用
- 临床前证据支持表观遗传调节剂治疗肾脏病的潜力,但需警惕部分药物的肾毒性。
局限性
- 大多数临床前研究针对CKD或AKI向CKD转化,AKI直接证据有限且矛盾。
- 许多表观遗传调节药物仍处于临床开发阶段,多用于恶性肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epigenetics refers to heritable changes in gene expression patterns not caused by an altered nucleotide sequence, and includes non-coding RNAs and covalent modifications of DNA and histones. This review focuses on functional evidence for the involvement of DNA and histone epigenetic modifications in the pathogenesis of kidney disease and the potential therapeutic implications. There is evidence of activation of epigenetic regulatory mechanisms in acute kidney injury (AKI), chronic kidney disease (CKD) and the AKI-to-CKD transition of diverse aetiologies, including ischaemia-reperfusion injury, nephrotoxicity, ureteral obstruction, diabetes, glomerulonephritis and polycystic kidney disease. A beneficial in vivo effect over preclinical kidney injury has been reported for drugs that decrease DNA methylation by either inhibiting DNA methylation (e.g. 5-azacytidine and decitabine) or activating DNA demethylation (e.g. hydralazine), decrease histone methylation by inhibiting histone methyltransferases, increase histone acetylation by inhibiting histone deacetylases (HDACs, e.g. valproic acid, vorinostat, entinostat), increase histone crotonylation (crotonate) or interfere with histone modification readers [e.g. inhibits of bromodomain and extra-terminal proteins (BET)]. Most preclinical studies addressed CKD or the AKI-to-CKD transition. Crotonate administration protected from nephrotoxic AKI, but evidence is conflicting on DNA methylation inhibitors for preclinical AKI. Several drugs targeting epigenetic regulators are in clinical development or use, most of them for malignancy. The BET inhibitor apabetalone is in Phase 3 trials for atherosclerosis, kidney function being a secondary endpoint, but nephrotoxicity was reported for DNA and HDAC inhibitors. While research into epigenetic modulators may provide novel therapies for kidney disease, caution should be exercised based on the clinical nephrotoxicity of some drugs.
引用
- Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease. Nephrol Dial Transplant. 2018. PMID: 29534238. doi:10.1093/ndt/gfy009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。